A Phase 1, Open-Label, Multi-Center, Dose-Finding, Pharmacokinetic, Safety And Tolerability Study Of Pf-07265807 In Participants With Selected Advanced Or Metastatic Solid Tumor Malignancies Read more
(CD47 And PD-L1) A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND ANTITUMOR ACTIVITY OF PF-07257876 IN PATIENTS WITH ADVANCED OR METASTATIC TUMORS FQ Completed On: 2/4/2021 Read more
A Two-Part, Phase 1a/B, Open-Label, Multicenter Trial Evaluating Pharmacokinetics, Safety And Efficacy Of Pf-07284890 (Arry-461) In Participants With Braf V600-Mutant Solid Tumors With And Without Brain Involvement Read more
Phase II Trial Of Autologous Rapamycin-Resistant Th1/Tc1 (RAPA-201) Cell Therapy Of Checkpoint Therapy Resistant Solid Tumors Read more
A Phase 1/2 Study Of Tpx-0131, A Novel Oral Alk Tyrosine Kinase Inhibitor In Subjects With Alk+ Advanced Or Metastatic Nsclc Read more
A Phase 2 Study Of VS-6766 (Dual RAF/MEK Inhibitor) As A Single Agent And In Combination With Defactinib (FAK Inhibitor) In Recurrent KRAS-Mutant (KRAS-MT) Non-Small Cell Lung Cancer (NSCLC) Read more
An Open-Label, Multicenter Phase I Dose Escalation Study To Characterize Safety, Tolerability, Preliminary Antitumor Activity, Pharmacokinetics And Maximum Tolerated Dose Of VIP152 (BAY 1251152) In Subjects With Advanced Cancer Read more
An expanded access protocol for mobocertinib in refractory Non-Small Cell Lung Cancer patients with EGFR exon20 insertion mutations Read more
